Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 599-608
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Table 1 Characteristics of solid tumor patients receiving coronavirus disease 2019 vaccination
| Patient characteristics | n = 210, % |
| Age at vaccination, median (range), yr | 70 (23-91) |
| Sex | |
| Male | 102 (49) |
| Female | 108 (51) |
| Race | |
| Caucasian | 183 (87) |
| African American | 19 (9) |
| Other | 8 (4) |
| Site of primary tumor | |
| Gastrointestinal | 92 (44) |
| Thoracic | 64 (30) |
| Genitourinary | 37 (18) |
| Other | 17 (8) |
| Type of systemic therapy | |
| Chemotherapy | 117 (56) |
| Immunotherapy | 51 (24) |
| Targeted therapy | 42 (20) |
- Citation: Cox RE, Parish M, Oxencis C, Mckenna E, Thapa B, Chakrabarti S. Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy. World J Clin Oncol 2022; 13(7): 599-608
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/599.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.599